Latest quarterly reviews
中文-
Nvidia Q3 2027: a $130 billion guide and a raised outlook in first report without Huang
Nvidia's $115.8 billion quarter beat its own guide by 7.3%; it guided to $130 billion and about 75% growth next year, as receivables and commitments grew again.
-
Rocket Lab Q3 2026: backlog up 52% to $3.6 billion as Neutron slips into 2027
Rocket Lab's sales beat its own range and backlog jumped 52%, but Neutron's first launch, which management ties to stand-alone adjusted profit, moved into 2027.
-
Hims & Hers Q3 2026: sales up 49%, but margins slide, subscribers dip and profit outlook cut
Hims & Hers grew sales 49% on weight loss and Eucalyptus, but gross margin fell to 57%, subscribers dipped from Q2 and it cut its 2026 profit outlook.
-
TG Therapeutics Q3 2026: Briumvi target raised again, but sales growth slows to 2% from Q2
TG Therapeutics raised its 2026 Briumvi target for the third time, to $915–920 million, but US sales rose only 2% from Q2 and the rest of the raise rests on Q4.
-
Immunocore Q3 2026: sales dip after Q2 stocking; key melanoma trial data slips to Q2 2027
Immunocore's Kimmtrak sales fell 12% from Q2 to $102.2 million after a stocking boost, and it now expects its key melanoma trial data in Q2 2027.
-
Vera Q3 2026: first Trutakna sales of $10.3M, about half inventory; a rival's FDA date nears
Vera reported first sales of $10.3 million, about half of it inventory, and filed for full approval; Vertex's rival drug has an FDA date of Nov 30.
-
Agios Q3 2026: record sales, R&D cuts, a 2028 non-GAAP profit goal; shares fall 10%
Agios sales rose 24% from Q2 and it set a 2028 non-GAAP profit goal and cut R&D jobs, but the shares fell about 10% as the sickle cell decision waits.
-
Astera Labs Q3 2026: big beat, a 53% buyer, shares 4% lower
Astera Labs beat forecasts and guided well above them, but one direct buyer reached 53% of sales and the shares closed 4.4% lower on Nov 4.
-
Madrigal Q3 2026: first profit and a sales beat, yet shares end 8% lower
Madrigal shares reversed an early 11% gain and closed 8.1% lower, even though sales beat forecasts and it reported its first quarterly profit.
-
Palantir Q3 2026: revenue up 96% and guidance raised again, but contract signings slow
Palantir beat its own Q3 revenue guide by about $150 million and raised its 2026 outlook, while new contract value grew 6% after 49% in Q2.
-
Coinbase Q3 2026: revenue flat at $1.2 billion as costs fall and a crypto gain lifts profit
Coinbase's Q3 revenue held at $1.22 billion as trading stayed weak; costs came in below its range, and a gain on its own crypto supplied most of its profit.
-
Alnylam Q3 2026: shares fall 25%; US demand adds less revenue than in Q2
Alnylam shares fell 25% on Oct 29 after Q3 showed less added US demand revenue, higher costs and two delayed data updates.
-
Viking Therapeutics Q3 2026: trials on track, spending up 44% and nearly $1 billion in cash
Viking's Q3 research expense rose 44% from Q2, and September financing lifted cash and short-term investments to $960 million. Its Phase 3 timelines held.
-
GE Vernova Q3 2026: guidance up again and a $9 billion deal, with Wind still the drag
GE Vernova raised its 2026 guidance again, agreed a $9B deal for Trench Group and doubled its buyback limit. Wind and Electrification orders are the watch points.